ImmunityBio, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company generated total revenue of $32.1 million for the quarter, a substantial increase of 425% compared to $6.1 million in the same period last year. This growth was primarily driven by product revenue from ANKTIVA, which amounted to $31.8 million, up from $6 million in the prior year. For the nine months ended September 30, 2025, total revenue reached $75 million, a 943% increase from $7.2 million in the same period of 2024. Despite this revenue growth, ImmunityBio reported a net loss of $67.3 million for the quarter, a 22% improvement from a net loss of $85.8 million in the prior year.
The company’s financial position has also seen notable changes. As of September 30, 2025, ImmunityBio had cash and cash equivalents of $60.2 million, down from $143.4 million at the end of 2024. However, marketable securities surged to $197.6 million from $6.4 million, reflecting a strategic shift in asset allocation. The total assets increased to $519 million, compared to $382.9 million at the end of 2024. The accumulated deficit grew to $3.7 billion, up from $3.4 billion, indicating ongoing investment in research and development and operational costs.
Strategically, ImmunityBio has made significant strides in its product offerings and market presence. The company received FDA approval for ANKTIVA in April 2024 and began commercial distribution in May 2024. In July 2025, the UK’s MHRA granted marketing authorization for ANKTIVA, marking its first approval outside the U.S. The company has also initiated several clinical trials, including a Phase 3 study for non-small cell lung cancer and a trial for glioblastoma, which reported promising early results. As of September 30, 2025, ImmunityBio employed 673 individuals, reflecting its commitment to expanding its workforce to support ongoing and future projects.
Operationally, ImmunityBio's revenue concentration remains a concern, with approximately 96% of total gross revenue derived from its top four customers. The company is actively working to diversify its customer base to mitigate risks associated with reliance on a limited number of clients. The filing also highlighted the company's ongoing efforts to secure additional financing to support its operations and product development, as it anticipates continued cash outflows related to the commercialization of ANKTIVA and the advancement of its product pipeline.
Looking ahead, ImmunityBio expressed optimism about its growth trajectory, emphasizing the potential for ANKTIVA to become a foundational therapy across various cancer treatments. However, the company acknowledged the uncertainties surrounding future revenues and the need for additional funding to sustain its operations and development efforts. The management remains focused on leveraging its innovative platforms to enhance the immune response against cancers and infectious diseases, while navigating the complexities of regulatory approvals and market acceptance.
About ImmunityBio, Inc.
ImmunityBio is a biotech company developing next-generation immunotherapies that activate the body's immune system to treat cancers and infectious diseases. Its core platforms include cytokine fusion proteins, cell therapies, and vaccine vectors, aimed at creating durable immune memory and overcoming tumor immune evasion. The company focuses on immuno-oncology, including cancer vaccines and therapies that reduce reliance on high-dose chemotherapy, serving global markets with innovative, accessible treatments.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.